Loading
Pegilodecakin, a long-acting interleukin-10 meant to expand tumour-killing T cells, added nothing to FOLFOX in the phase 3 SEQUOIA trial of second-line pancreatic cancer, and Eli Lilly dropped it.
Pegylated interleukin-10 raised CD8 T cell activity in early studies, and ARMO BioSciences (bought by Eli Lilly in 2018) took it into SEQUOIA: 567 patients whose metastatic pancreatic cancer had progressed on gemcitabine-based therapy (94.7 percent after gemcitabine and nab-paclitaxel) randomised to FOLFOX with or without pegilodecakin. Median overall survival was 5.8 against 6.3 months (hazard ratio 1.045), progression-free survival 2.1 months in both arms and response 4.6 against 5.6 percent; thrombocytopenia (55 against 20 percent) and anaemia (40 against 16 percent) were commoner with the cytokine while immune markers moved as predicted. Five UK sites took part (Cambridge, Hammersmith, Velindre Cardiff, University College London Hospitals, Guy's and St Thomas').
Interleukin-10 receptor agonism, expanding and activating tumour-infiltrating CD8 T cells while suppressing inflammatory myeloid signalling.
1.Pegilodecakin binds its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pegilodecakin" OR ABSTRACT:"Pegilodecakin" OR TITLE:"AM0010" OR ABSTRACT:"AM0010" OR TITLE:"LY3500518" OR ABSTRACT:"LY3500518" OR TITLE:"Pegylated interleukin-10" OR ABSTRACT:"Pegylated interleukin-10") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pegilodecakin, not a curated reading list.
Shares Hot vs cold tumours, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Hot vs cold tumours, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.